The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
BIOHAVEN LTD | COM | G1110E107 | 70,241,247 | 2,936,507 | SH | DFND | 1 | 2,936,507 | 0 | 0 | ||
VIRACTA THERAPEUTICS INC | COM | 92765F108 | 5,217 | 3,700 | SH | DFND | 1 | 3,700 | 0 | 0 | ||
BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 27,076,924 | 3,846,154 | SH | DFND | 1 | 3,846,154 | 0 | 0 |